Form 4: Arcutis EVP Sells Shares Under Pre-Arranged 10b5-1 Plan

Patrick Burnett, Arcutis Biotherapeutics' EVP and Chief Medical Officer, sold 2,490 shares of common stock at a weighted average price of $28.98 per share through a pre-scheduled 10b5-1 trading plan.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc. (ARQT), sold 2,490 shares of common stock.
• The transaction occurred on January 5, 2026, at a weighted average price of $28.9822 per share.
• The shares were sold in multiple transactions within a price range of $28.77 to $29.19.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
• Following this transaction, Patrick Burnett beneficially owns 94,120 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sale of shares by an executive is generally neutral when conducted under a pre-arranged 10b5-1 plan, as it typically reflects personal financial planning rather than a signal about the company's operational performance or future prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information about the company's performance.

Negatives

• The transaction represents a reduction in direct beneficial ownership by a key executive, with 2,490 shares of common stock sold.

Risks

• Insider selling, even when pre-planned, can sometimes be perceived negatively by investors, potentially leading to short-term downward pressure on the stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology sector as executives manage personal finances and diversify holdings. While a sale reduces insider ownership, the pre-scheduled nature often mitigates concerns about its implications for the company's immediate prospects.

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a key executive, though the pre-planned nature of the sale under a 10b5-1 plan typically lessens concerns about its implications for the company's future.

Key Dates

Recommendation

The sale of shares by Executive Vice President and Chief Medical Officer Patrick Burnett was executed under a pre-arranged 10b5-1 trading plan. Such plans are established in advance and are not typically indicative of new, material non-public information. While it represents a reduction in insider ownership, it does not provide a strong signal for either a buy or sell recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Arcutis Biotherapeutics, ARQT, insider trading, Form 4, stock sale, 10b5-1 plan, Patrick Burnett